{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+the+Pancreas&page=15", "query": { "condition": "Adenocarcinoma of the Pancreas", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 929, "total_pages": 93, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+the+Pancreas&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+the+Pancreas&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T00:48:23.144Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00766636", "title": "Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2008-09", "completion_date": null, "has_results": true, "last_update_posted_date": "2016-05-19", "last_synced_at": "2026-10-15T00:48:23.144Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00766636" }, { "nct_id": "NCT01783171", "title": "Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Adenocarcinoma", "Recurrent Pancreatic Carcinoma", "Stage III Pancreatic Cancer AJCC v6 and v7", "Stage IV Pancreatic Cancer AJCC v6 and v7", "Unresectable Pancreatic Carcinoma" ], "interventions": [ { "name": "Akt Inhibitor MK2206", "type": "DRUG" }, { "name": "Dinaciclib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2013-01-15", "completion_date": "2016-07-12", "has_results": false, "last_update_posted_date": "2017-08-22", "last_synced_at": "2026-10-15T00:48:23.144Z", "location_count": 4, "location_summary": "Aurora, Colorado • Denver, Colorado • Baltimore, Maryland + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01783171" }, { "nct_id": "NCT07189195", "title": "TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "Metastatic Pancreatic Adenocarcinoma", "Refractory Pancreatic Adenocarcinoma", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Malignant Solid Neoplasm", "Unresectable Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "TR-002", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2025-11-07", "completion_date": "2030-02-07", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-15T00:48:23.144Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07189195" }, { "nct_id": "NCT01770353", "title": "MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "ER/PR Positive Breast Cancer", "Triple Negative Breast Cancer", "Metastatic Breast Cancer With Active Brain Metastasis" ], "interventions": [ { "name": "Ferumoxytol", "type": "DRUG" }, { "name": "MM-398", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2012-11", "completion_date": "2018-10-02", "has_results": true, "last_update_posted_date": "2019-11-27", "last_synced_at": "2026-10-15T00:48:23.144Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01770353" }, { "nct_id": "NCT00003798", "title": "Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Cancer of the Pancreas That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "motexafin gadolinium", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2000-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-11-14", "last_synced_at": "2026-10-15T00:48:23.144Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003798" }, { "nct_id": "NCT00049348", "title": "Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "epoetin alfa", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2003-10-13", "completion_date": "2009-05", "has_results": false, "last_update_posted_date": "2023-06-15", "last_synced_at": "2026-10-15T00:48:23.144Z", "location_count": 137, "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Boca Raton, Florida + 93 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00049348" }, { "nct_id": "NCT00769483", "title": "MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "MK-0646", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2008-11-13", "completion_date": "2020-09-01", "has_results": true, "last_update_posted_date": "2020-09-03", "last_synced_at": "2026-10-15T00:48:23.144Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00769483" }, { "nct_id": "NCT00088894", "title": "Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Adenocarcinoma of the Pancreas", "Recurrent Pancreatic Cancer", "Stage II Pancreatic Cancer", "Stage III Pancreatic Cancer", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacogenomic studies", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2004-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-05", "last_synced_at": "2026-10-15T00:48:23.144Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00088894" }, { "nct_id": "NCT03484299", "title": "Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreas Cancer" ], "interventions": [ { "name": "Irreversible Electroporation (IRE)", "type": "PROCEDURE" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "FOLFIRINOX", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "University of Louisville", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2018-05-30", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-10-15T00:48:23.144Z", "location_count": 1, "location_summary": "Louisville, Kentucky", "locations": [ { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03484299" }, { "nct_id": "NCT05275075", "title": "Identify microRNAs in Cachexia in Pancreatic Carcinoma", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Resectable Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Pancreatic cancer microRNA and messenger RNA expression.", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2022-12-07", "completion_date": "2026-04-03", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-10-15T00:48:23.144Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT05275075" } ] }